Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revive has nothing. You're both right.
Go play yer simple minded word games with your mental midget friends eejit.
I agreed with ye. I said you were right. I thought we kind of bonded on this one.
If thats your assessment of my post then I suggest you go back to school and learn how to read and comprehend what ye read.
Hmmm...it seems to me that Snoop dog said pretty much the same thing you did in your next post. He was just more to the point and did it in a fraction of the words that you did. Revive has nothing. You're both right.
Formalizing the merger would be a solid for Revive……AIMHO
Yes follow. They’re making some solid strides lately. Looking for more solid positioning Q2.
Do you follow Pharmathera?
No i dont. Before the collaboration I saw that both companies were closely linked at the management level.
Still believe as I did back then that there will be a formal merger/consolidation at some point.
AIMHO
Hey Rick! Thank you for your insight. Do you follow Pharmathera? I’ve been invested since .10
The science is now trending away from traditional needles to these types of patches for vaccine delivery.
Several of the usual suspects (Bill Gates etc) have already, or started investing in companies pioneering this tech.
IF MF can finally finalize some type of deal with a large biotech to utilize this patch for drug delivery it could bear fruit at some point.
Stressing on "st some point" since unlike what happened during covid, the days of quick approvals are gone, except for the chosen few of course.
As for the psych end of the business, IMO that sector is still in its infancy as the legislation to legalize its use and the science is still limited in scope.
Contrary to the narrative by the usual suspects, Long Covid isnt going anywhere anytime soon but time is indeed of the essence as Revive is surely not the only company looking into formulating some kind of treatment for the vast numbers of LC sufferers in the USA and Worldwide.
It now all rests on MF being able to finally execute just one, or all of his projects but until that happens I will simply keep a watchful eye and hold.
And yet youre uncontrollably compelled to keep coming here time after time to regurgitate the same tripe.
Would think one would have better things to do with ones valuable time innit!
Wanker!!!
Looks like the scam is still alive. By a time gets approval for long Covid. There won't be a long COVID anymore. Lol They got no data. Just BS. Nothing is coming out of this turd. RS is next. And then start diluting again. ATM pay MF salary.
Still hold some here but I need to get real
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173739479
Still hold some here but I need to get real
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173739479
Anyone looking for 1 more investment emge... mf Sucks if he brought on the guy Bmt wanted pps maybe better lol... hate it bucillamine I know good drug but Chit managed....
I'm just waiting for the R/S.
Is anyone keeping up with progress and what it could mean for 2024 pps?
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
February 03, 2023 06:00 ET
| Source: Revive Therapeutics Ltd.
Follow
TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM) to evaluate the delivery of 3,4-Methylenedioxy?methamphetamine (“MDMA”) using PharmaTher’s novel microneedle patch (“MN-Patch”) delivery technology.
Michael Frank, CEO of the Company, commented, "We are excited about the potential of the MDMA microneedle patch, which will complement our psilocybin programs for mental health and abuse disorders. We look forward to advancing the MDMA patch program that could fill the gaps that we believe could offer an advantage to oral MDMA treatments.”
PharmaTher has completed a non-clinical research study evaluating the delivery of its MDMA MN-Patch. Research results from this study will be available in early Q2-2023 and will be used to support a potential human clinical study. Based on the results, Revive and PharmaTher will finalize a product and clinical development plan to initiate regulatory discussions for future clinical studies in various indications where MDMA may have promise, including depression, anxiety, abuse disorders (i.e. eating, alcohol and drug use), and post-traumatic stress disorder (“PTSD”).
Currently, the nonprofit Multidisciplinary Association for Psychedelic Studies (“MAPS”), through its wholly-owned subsidiary, MAPS Public Benefit Corporation (“MAPS PBC”), has completed two confirmatory Phase 3 trials of MDMA-assisted therapy for PTSD to potentially support its new drug application to be filed with the U.S. Food and Drug Administration (“FDA”) in 1H-2023. The FDA decision for potential approval of MDMA-assisted therapy for PTSD is expected in 2024.
In addition to developing bucillamine for infectious diseases and rare disorders, Revive is building a specialty psychedelics program, which includes psilocybin and MDMA to treat mental health and abuse disorders.
The Company’s psilocybin programs include:
evaluating psilocybin in a Phase 1/2 clinical study for methamphetamine use disorder via a research collaboration with the University of Wisconsin-Madison.
developing a novel psilocybin oral thin film strip through a feasibility agreement with LTS Lohmann Therapie-Systeme AG, a leader in pharmaceutical oral thin films.
developing a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform under its research collaboration with North Carolina State University.
This collaboration will allow Revive to evaluate the results of PharmaTher’s MDMA MN-Patch for indications that do not overlap with the Company’s psilocybin initiatives. The Company believes that the MDMA MN-Patch may enable flexible drug load capacity and combinations, controlled released delivery, and be able to present desired pharmacokinetic and safety profiles which could overcome the potential obstacles of oral dosing.
About the MN-Patch Technology
The microneedle patch delivery technology is based on novel biocompatible and biodegradable gelatin methacryloyl (“GelMA”) material to deliver water-soluble and insoluble drugs with desirable release profiles safely. The GelMA-based microneedle patch can efficiently penetrate the stratum corneum layer (outer layer of the skin), enable flexible drug load capacity and combinations, and control-release delivery. Microneedles are considered a promising way to achieve systemic effects by transdermal delivery of drugs, including psychedelics, and circumventing absorption and first-pass barriers typical for oral delivery. In addition, it aims to empower patients to self-dose safely and incorporates anti-tampering and anti-abuse features.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a specialty pharmaceutical company focused on developing and commercializing KETARX™ (racemic ketamine) for mental health, neurological and pain disorders. Learn more at PharmaTher.com.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
The chap makes total sense but unfortunately the worldwide health bureaucracy and drug co. muppets are more interested in developing novel vaccs and drugs instead of focusing more resources on repurposing existing treatments through testing.
Gotta fund the 30k per month salary the shareholders hand to him for playing golf and smoking Cubans. When are the shareholders going to wake up?
Annual offerings lol. MF is a dilution machine
https://finance.yahoo.com/news/revive-therapeutics-ltd-announces-offering-225500147.html
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TO...
Could be a longer slog than was expected but will be worth the wait IMO!
https://revivethera.com/2024/01/revive-therapeutics-provides-update-evaluating-bucillamine-for-nerve-agent-exposure-with-defence-research-and-development-canada/
Two things stand out. One- the short trial timetable: Two- The interest in Bucy as a tool for seizure prevention. Time will tell.
Play the volatility is a good plan. It might take some time but hope you get to even. What a rollercoaster ride this has been.
If, and I say IF, the new formulation proves to be a success and can be monetized, the constant bollocks being spewed here will cease post haste.
As with virtually every Biotech, whether well funded or not, it all hinges on the product being effective.
In case everyone hasn't realized as of yet, this space has, for some time now, reverted to the snail pace (for most that is) that it previously operated under, and by that I mean a ""rigid"" clinical process (again, for most, not all).
This means the wait could be long BUT very profitable IMO for those who held.
Thanks for your ever irrelevant opinion.....stressing on IRRELEVANT!
I've already sold most of my shares and going to take the loss to counter my gains in other stocks. I recently bought more however and have made some of the money back, on paper, in the new year.
With all due respect, the end has already happened my friend. The game is over. The truth is already out. Acceptance is the first step to recovery.
Yada...yada...yada. Same old talk for 4 years now. This company is a scam and you are 100% wrong again. At least your consistent. Now show some real consistency and hold the fantasizers accountable, otherwise you're credibility is dead.
So many nasty posters on here, kind of like the world today. Relax, say your piece but don't tear down others just to make a point. In the end, someone will be right, then the truth will come out.
Revive is showing new signs of life in terms of the company's progress whereas there is nothing but BS from you yet again. In fact, you are so lacking in intelligence (among every other finer quality trait / attribute a decent adult possesses), you have failed to observe that I generally don't talk about the stock or it's performance > I occasionally respond to you - a super-turd and pitiful sad act - due to your despicable approach, presence and overall being. In total I have probably devoted 4 mins of my life to you thus far. Too much in any case.
You’re forgetting one fact. You have been wrong 100% of the time. You can run but you can’t hide from that. Optimism of toxic positivity?
It is clear that you desperately need attention or paid post dollars. Or Both - which is likely. Your response there doesn't make any sense, little dweeb. Frankly you are communicated to the way your deserve to be based on your appalling, spiteful attitude plus the flawed content of most of your posts. Ecomike is nothing like you whatsoever so drop the amusingly sad attempt at any comparison. I share in much of his optimism and various points of view.
Now buzz off and flush back down the nearest toilet
Hey Nosy, when are you going to hold yourself to your own standards? What kind of person practices do as I say not as I do? I see you gave Egomike a free pass too. Try some credibility my man. I know it’s hard when you’ve been 100% wrong the entire way, but you still have time. Good luck!
Thanks. The websites I was going to did not show these insider transactions. MF is a problem that will always be a problem and a barrier. Good luck to you.
Have no idea lol,. but some bought recently at .05, they need Funding and some good data eventually I think, but can that happen with mf? is bmt right I really don't know ...I was going to buy some more but decided to buy rakr for a merger play possible ,05 to .10 jan22 1000% to 2000% gain maybe, see what happens lol. im still waiting to buy back in more soon here maybe..
https://ceo.ca/rvv
Filed 2024-01-05 09:50
Tx date 2024-01-02 $RVV
Revive Therapeutics Ltd. Lindzon, Andrew Stuart
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+400,000 vol 1,650,000
Filed 2024-01-04 13:48
Tx date 2024-01-02 $RVV
Revive Therapeutics Ltd. Scovenna, Christian
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options $20,000
+400,000 vol
$0.05 each 1,650,000
Filed 2024-01-04 13:41
Tx date 2024-01-02 $RVV
Revive Therapeutics Ltd. Jackson, William
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options $20,000
+400,000 vol
$0.05 each 1,400,000
Filed 2024-01-04 13:37
Tx date 2024-01-02 $RVV
Revive Therapeutics Ltd. Frank, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options $100,000
+2,000,000 vol
$0.05 each 16,500,000
Filed 2024-01-04 13:36
Tx date 2024-01-02 $RVV
Revive Therapeutics Ltd. Frank, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options $100,000
+2,000,000 vol
$0.05 each
Filed 2024-01-04 13:35
Tx date 2022-11-29 $RVV
Revive Therapeutics Ltd. Frank, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options $-32,500
-100,000 vol
$0.325 each 14,500,000
Filed 2024-01-04 13:34
Tx date 2022-11-01 $RVV
Revive Therapeutics Ltd. Frank, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options $-50,000
-250,000 vol
$0.20 each 14,600,000
Filed 2024-01-04 13:31
Tx date 2024-01-02 $RVV
Revive Therapeutics Ltd. Frank, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options $100,000
+2,000,000 vol
$0.05 each
A dime? Hmmm....but you said this on 12/22/2020:
"I see $RVVTF reaching $2 to $3 on clinical trial news or just before it.
I see the big boys like Goldman sucks and their high speed trading computers running this up $10 in the days of EUA FDA committee meetings and pre decision making, to do an offering at no less than $5/share to raise a pile of cash for RVVTF before any one knows what is cooking.
That will put a pile of serious cash into RVVTF for years as bid Support at $5/share
I think the big run starts in January. and breaks are least $3 in January, that is my educated guess."
Fair enough. If you play the volitility you just might do alright and come out okay. Why do you think no insiders are buying at these prices?
LOL. Zip it, little street urchin. Your (paid?) flawed posts will change nothing so be gone and perhaps live a better life.
1) It is not and never was game.
2) The fat lady has not sung
3) This is not one trick horse stock
4) OTC has come back to life with a vengeance
5) Plenty real stuff going on with this stock.
6) Not my first rodeo.
7) Long Live $RVVTF
8) Shorts are going bankrupt, deep under water in the US Market already.
9) Next news could run us to a dime
yea yea...still thinking about buying back in and adding to my smaller amount I have now after selling a lot I'm not sure yet because I'm still bearish with the Mfer lol...
Ps. But Not Bucillamine
Fool me once shame on you, fool me twice shame on me.
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillaminehttps://t.co/WXxJeRIsIk$RVV $RVVTF #Bucillamine #InfectiousDiseases #pharmaceuticals pic.twitter.com/rxhKt7zSQp
— Revive Therapeutics (CSE: RVV, US: RVVTF) Official (@Revive_RVV) January 10, 2024
The game is over Mike, and it was over a long time ago.
Might get more awareness about Bucy it looks..I remember this guy tweeting some about the Phase 3 trial before...
I still hold some but was still hoping to buy back in the shares I had but none of my 3 other stocks are doing good, and been averaging down in the bio one lately.
I am still Bearish as hell with Mf lol..but not Bucillamine when I sold a lot my average was .15 or so here, so still lost a lot, and I think it can go 5 times or more from here if the mfer don't f up lol
Ps. Still plan to buy back in more if I somehow get more.or make money back from other stock.
contact me in DM so we can discuss in more details - thanks
— Chris Turnbull (@EnemyInAState) January 9, 2024
My thoughts on the bash-tards of RVVTF
Back in the day a great “town”. Now it’s like every other aggressive, big city. Good luck to you as well with all of your investments!
I was in Houston in 1984. Nice town. GLTU on your investments.
Yes, 20 years ago I was caring for three babies. I had three little ones all under the age of 3 yrs. My husband and I lived in Houston as well. 1990 until 2002 then we moved to Dallas.
Are you really caring for 3 babies? I lived in TX when I had a job at Exxon downtown Houston. 20 years ago.
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |